Cas:33524-31-1 2,5-dimethoxybenzyl alcohol manufacturer & supplier

Chemical Name:2,5-dimethoxybenzyl alcohol

CAS.NO:33524-31-1

Synonyms:2,5-Dimethoxybenzyl alcohol;EINECS 251-562-0;(2,5-dimethoxyphenyl)methan-1-ol;2,5-Dimethoxy-benzylalkohol;MFCD00004615;2,4-DIMETHOXYBENZOYLACETONITRILE;11-Oxy-2.5-dimethoxy-1-methyl-benzol;(2,5-Dimethoxyphenyl)methanol;Benzenemethanol,2,5-dimethoxy

Molecular Formula:C₉H₁₂O₃

Molecular Weight:168.19000

HS Code:2909499000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:122-125 °C1 mm Hg(lit.)

Density:1.173 g/mL at 25 °C(lit.)

Index of Refraction:n20/D 1.547(lit.)

PSA:38.69000

Exact Mass:168.07900

LogP:1.19610

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 2,5-Dimethoxybenzyl alcohol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzenemethanol,2,5-dimethoxy physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 251-562-0 Use and application,MFCD00004615 technical grade,usp/ep/jp grade.

Related News: The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 2,5-dimethoxybenzyl alcohol manufacturer Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. 2,5-dimethoxybenzyl alcohol supplier The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 2,5-dimethoxybenzyl alcohol vendor Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. 2,5-dimethoxybenzyl alcohol factory Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.